17Beta-estradiol increases basal but not bradykinin-stimulated release of active t-PA in young postmenopausal women

What Was Tested

Researchers studied Bradykinin in this randomized controlled trial publication.

Angiotensin-converting enzyme inhibition potentiates basal and bradykinin-stimulated tissue-type plasminogen activator (t-PA) release to a greater extent in women than in men.

This study tested the hypothesis that 17beta-estradiol enhances the effect of angiotensin-converting enzyme inhibition on t-PA release in young postmenopausal women.

Who Took Part

The abstract describes 14 women taking part.

By PubMed's age tags, the people studied were middle-aged adults, women only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Bradykinin and who got the comparison, which limits bias.

As a double-blind Bradykinin study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Bradykinin could be set against what happens without it.

Each person switched between Bradykinin and the comparison at some point, usually with a gap in between.

A time span of 4 weeks appears in the methods.

What Was Measured

This study tested the hypothesis that 17beta-estradiol enhances the effect of angiotensin-converting enzyme inhibition on t-PA release in young postmenopausal women.

The subject headings attached to it are Age Factors, Angiotensin-Converting Enzyme Inhibitors, Bradykinin, Drug Interactions, Enalaprilat, Estradiol and Estrogens.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Bradykinin in 14 women over 4 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2008 (Hypertension (Dallas, Tex. : 1979)), a journal based in United States.

More context: the Bradykinin compound page, all human trials.